Serum Institute of India Rollout Covishield

India biotech and biopharma major Serum Institute of India (SII) has informed the union government that the company will manufacture and supply nine to 10 crore Covishield doses in June, news agency PTI reported quoting official sources. The development comes amidst complaint by states about the shortage of anti-Covid-19 vaccines.

SII, in a letter to the Union Home Minister Amit Shah, said that the company’s employees have been working round the clock despite various challenges posed by the pandemic. “We are pleased to inform that in the month of June we will be able to manufacture and supply nine to 10 crore doses of our Covishield vaccine to the country as compared to our production capacity of 6.5 crore doses in May,” Prakash Kumar Singh, the company’s Director of Government and Regulatory Affairs said in the letter.

“Serum Institute of India has always been sincerely concerned about the protection of the citizens of our country and world at large from Covid-19. Under the leadership of our CEO, Adar C Poonawalla, our team has been working relentlessly shoulder to shoulder with our government to fight the Covid-19 pandemic,” Singh also said in the letter. “We assure you that with the support of the Government of India and under your kind guidance, we are trying our best by utilising all of our resources to increase our production capacity of Covishield in the coming month also.”


Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related News